SLURP1 and pancreatic ductal adenocarcinoma: In addition, the efficiency of SLURP-1 has also been demonstrated against various carcinoma and glioma cells in vitro, including SKBR3 breast carcinoma, MCF-7 breast carcinoma, HT-29 colorectal adenocarcinoma, and pancreatic ductal adenocarcinoma, and gliomas U251 MG and A172 (Lyukmanova et al., 2014; 2018; Throm et al., 2018; Bychkov et al., 2019; 2021; Shulepko et al., 2020a; 2023).